Tachycardia: The increasing consumption of alcohol and the rate of cardiovascular disorders is likely to drive the growth of the global market at CAGR of 10.10%

Pune, India, 2022 /MRFR Press Release/- Market Research Future (MRFR) announces the publication of its research report – Global Tachycardia Market, 2022 -2030

Tachycardia Market Highlights

Tachycardia is a common type of heart disorder, which results in a faster heartbeat. Tachycardia can be caused due to various conditions such as heart diseases including coronary artery disease, drinking large amounts of alcohol, and medical conditions such as thyroid disease and certain lung diseases.

The global Tachycardia Market is expected to be valued at USD 1045.23 Million by 2030, growing at an 10.10% CAGR during forecast 2022-2030.

Regional Analysis

The Americas dominates the global tachycardia market owing to the increasing aging population, which eventually leads to increase in patient population. Additionally, increasing obesity rates along with increasing cardiovascular disorder rates is likely to enhance the growth of tachycardia in the North American region. According to the American Heart Association, 31% of deaths in the U.S. were due to cardiovascular disorders. Similarly, according to the National Institute on Alcohol Abuse and Alcoholism, in 2015 around 15.1 million adults of 18 and above in the U.S. had alcohol use disorder. This alarming rate of cardiovascular disorders and alcoholism is likely to drive the growth of tachycardia market in the Americas.

Europe accounts for the second largest market due to increasing cardiovascular disorders and obesity rates. Additionally, the increasing government support and increasing healthcare infrastructure are driving the growth of the tachycardia market in Europe. For instance, Eurostat estimated that over 19.2% of the population in Europe was aged 65 and above. This increasing older population is likely to lead to increase in the patient population. These factors are likely to drive the growth of the tachycardia market.

Asia Pacific is the fastest growing market for tachycardia whose growth is attributed to the increasing population and increasing standard of living. Additionally, the increasing healthcare expenditure and demand for new treatment options along with the rise in government support are likely to drive the growth of the market. India and China are the major contributors to the market growth due to the rapid development of the healthcare infrastructure in these regions and increasing demand for diagnostic services.

On the other hand, the Middle East and Africa is expected to witness a limited growth due to limited access to healthcare and lack of awareness among individuals. In the Middle East, the growth of the market is driven by the increasing availability of new and advanced diagnostic and treatment methods for various chronic diseases.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Tachycardia Market Research Report

Segmentation

The global tachycardia market is segmented on the basis of type, treatment, diagnosis, and end-user.

On the basis of type, the market is segmented into atrial fibrillation, atrial flutter, supraventricular tachycardia, ventricular tachycardia, ventricular fibrillation, and tachy-brady syndrome. 

On the basis of treatment, the market is segmented into vagal maneuvers, medications, and cardioversion. On the basis of diagnosis, the market is segmented into imaging tests, electrocardiogram, and stress test.  On the basis of imaging tests, it is further sub-segmented into echocardiogram, MRI, CT scan, coronary angiogram, and chest X-ray.

On the basis of end-user, the market is segmented into ambulatory surgical centers, specialty centers, and hospitals and clinics.

Key Players

Some of the key players in the tachycardia market are TZ Medical, Cardiva Medical Inc., Medtronic plc, Terumo Corporation Essential Medical, Inc., Merit Medical Systems, Inc., Abbott, Cardinal Health Inc., Inc., and Vasorum Ltd